E6011(抗FKN单抗)治疗MTX应答不足的活动性RA的II期研究
这项II期双盲安慰剂对照研究纳入190例MTX应答不足的活动性RA患者,随机接受安慰剂或E6011 100mg、200mg、400/200mg皮下注射24周。主要终点第12周ACR20应答率组间无显著差异,但第24周200mg和400/200mg组ACR20显著优于安慰剂,药物耐受性良好。
要点
- 第12周ACR20主要终点未达统计学显著差异。
- 第24周200mg和400/200mg组ACR20应答率显著高于安慰剂。
- 基线CD16+单核细胞比例高的患者亚组疗效更明显。
核心结论
- E6011靶向FKN-CX3CR1相互作用,治疗24周对RA有中等疗效,但主要终点未达到。
研究设计与样本
- II期随机双盲安慰剂对照研究,190例MTX应答不足的中重度活动性RA患者按2:1:2:2随机分组。
- 患者接受皮下注射安慰剂或E6011 100mg、200mg、400/200mg,第0、1、2周给药后每2周一次,共24周。
主要发现
- 第12周ACR20应答率(非应答者填补)为安慰剂37.0%、100mg组39.3%、200mg组48.1%、400/200mg组46.3%,与安慰剂差异无统计学意义。
- 第24周ACR20应答率为安慰剂35.2%、100mg组39.3%、200mg组53.7%、400/200mg组57.4%,200mg和400/200mg组达统计学显著。
- 探索性亚组分析显示基线CD16+单核细胞比例较高的患者第24周ACR20应答率为安慰剂30.0%、100mg组46.7%、200mg组57.7%、400/200mg组69.6%。
临床怎么用
- E6011 200mg和400/200mg方案在24周时显示优于安慰剂的ACR20应答,可作为后续研究剂量参考。
- 基线CD16+单核细胞比例可能有助于筛选更可能获益的患者。
局限性
- 主要终点第12周ACR20未达统计学显著差异。
- 亚组分析为探索性,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of E6011, a humanized IgG2 monoclonal antibody against human fractalkine (FKN), in a phase II, double-blind, placebo-controlled study in rheumatoid arthritis (RA) patients. METHODS: Patients with moderate-to-severe RA who had an inadequate response to methotrexate were randomly assigned to a placebo group or to E6011 100-mg, 200-mg, or 400/200-mg groups at a 2:1:2:2 ratio. During the 24-week period, patients received the study drug subcutaneously at weeks 0, 1, and 2 and then once every 2 weeks. The primary end point was the American College of Rheumatology 20% improvement criteria (ACR20) response rate at week 12. RESULTS: Study drugs were administered to 190 patients (placebo, n = 54; E6011 100 mg, n = 28; E6011 200 mg, n = 54; E6011 400/200 mg, n = 54), and 169 patients completed treatment. A significant difference from placebo was not found in ACR20 response rates at week 12 (37.0% [placebo], 39.3% [100 mg], 48.1% [200 mg], and 46.3% [400/200 mg], using nonresponder imputation). As a secondary end point, ACR20 response rate in the 200-mg and 400/200-mg groups attained statistical significance at week 24 (35.2% [placebo], 39.3% [100 mg], 53.7% [200 mg], and 57.4% [400/200 mg]). Subsequent exploratory subgroup analysis revealed greater efficacy of E6011, particularly in patients with a higher baseline proportion of CD16+ monocytes; ACR20 response rates in this patient subgroup at week 24 were 30.0% (placebo), 46.7% (100 mg), 57.7% (200 mg), and 69.6% (400/200 mg). E6011 administered for 24 weeks was well tolerated. CONCLUSION: This is the first evidence that E6011, a novel cell trafficking inhibitor targeting the FKN-CX3 CR1 interaction, is modestly effective with 24 weeks of treatment in RA patients, although the primary end point was not met.
引用
- Tanaka Y, Takeuchi T, Yamanaka H, et al. Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Study. Arthritis Rheumatol. 2021. PMID: 33038062. doi:10.1002/art.41555
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。